Increased very long-chain fatty acids in erythrocyte membranes of patients with aceruloplasminemia

Neurology

Volumn 50, Issue 1, 1998, Pages 130-136

  Miyajima, H ^a,b,c   Adachi, J ^a   Tatsuno, Y ^b   Takahashi, Y ^c   Fujimoto, M ^c   Kaneko, E ^b   Gitlin, J D ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LONG CHAIN FATTY ACID;

ADULT; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BASAL GANGLION; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; DIABETES MELLITUS; ERYTHROCYTE MEMBRANE; FATTY ACID OXIDATION; FEMALE; HUMAN; IRON METABOLISM; MALE; METABOLIC DISORDER; NERVE DEGENERATION; PATHOGENESIS; PRIORITY JOURNAL; RETINA DEGENERATION; TISSUE INJURY;

EID: 0031907553     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.1.130     Document Type: Article

References (28)

1. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987;37:761-767.
2. Logan JI, Harveyson KB.Wisdom GB, Hughes AE, Archbold GPR. Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus. QJM 1994;87:663-670.
3. Morita H, Ikeda S, Yamamoto K, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 1995;37:646-656.
4. Miyajima H, Takahashi Y, Shimizu H, Sakai N, Kamata T, Kaneko E. Late onset diabetes mellitus in patients with hereditary aceruloplasminemia. Intern Med 1996;35:641-645.
5. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RTA, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995;92:2539-2543.
6. Yoshida K, Furihata K, Takeda S, et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995;9:267-272.
7. Daimon M, Kato T, Kawanami T, et al. A nonsense mutation of the ceruloplasmin gene in hereditary ceruloplasmin deficiency with diabetes mellitus. Biochem Biophys Res Commun 1995;217:89-95.
8. Takahashi Y, Miyajima H, Shirabe S, Nagataki S, Suenaga A, Gitlin JD. Characterization of a nonsense mutation in the ceruloplasmin gene resulting in diabetes and neurodegenerative disease. Hum Mol Genet 1996;5:81-84.
9. Harris ZL, Migas MC, Hughes AE, Logan JI, Gitlin JD. Familial dementia due to a frameshift mutation in the caeruloplasmin gene. QJM 1996;89:355-359.
10. Okamoto N, Wada S, Oga T, et al. Hereditary ceruloplasmin deficiency with hemosiderosis. Hum Genet 1996;97:755-758.
11. Halliwell B, Gutteridge JMC. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 1986;246:501-514.
12. Gutteridge JMC, Richmond R, Halliwell B. Oxygen freeradicals and lipid peroxidation: inhibition by the protein ceruloplasmin. FEES Lett 1980;112:269-272.
13. Gutteridge JMC. Antioxidant properties of caeruloplasmin towards iron- and copper-dependent oxygen radical formation. FEES Lett 1983;157:37-40.
14. Miyajima H, Takahashi Y, Serizawa M, Kaneko E, Gitlin JD. Increased plasma lipid peroxidation in patients with aceruloplasminemia. Free Radie Biol Med 1996;20:757-760.
15. Klomp LWJ, Farhangrazi ZS, Dugan LL, Gitlin JD. Ceruloplasmin gene expression in the murine central nervous system. J Clin Invest 1996;98:207-215.
16. Miyajima H, Takahashi Y, Kamata T, Shimizu H, Kaneko E, Gitlin JD. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 1997;41:404-407.
17. Miwa A, Adachi J, Mizuno K, Tatsuno Y. Very long-chain fatty acid pattern in crush syndrome patients in the Kobe earthquake. Clin Chim Acta 1997;258:125-135.
18. Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem 1957;226:497-509.
19. Moser HW, Moser AB, Frayer KK, et al. Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology 1981;31:1241-1249.
20. Van den Bosch H, Schutgens RBH, Wanders RJA, Tager JM. Biochemistry of peroxisomes [review]. Ann Rev Biochem 1992; 61:157-197.
21. Schutgens RBH, Bouman IW, Nijenhuis AA, Wanders RJA, Frumau MEJ. Profiles of very-long-chain fatty acids in plasma, fibroblasts, and blood cells in Zellweger syndrome, X-linked adrenoleukodystrophy, and rhizomelic chondrodysplasia punctata. Clin Chem 1993;39:1632-1637.
22. Aoyama T, Souri M, Kamijo T, Ushikubo S, Hashimoto T. Peroxisomal acyl-coenzyme A oxidase is a rate-limiting enzyme in a very-long-chain fatty acid ß-oxidation system. Biochem Biophys Res Commun 1994;201:1541-1547.
23. Gulati S, Ainol L, Orak J, Singh AK, Singh I. Alterations of peroxisomal function in ischemia-reperfusion injury of rat kidney. Biochim Biophys Acta 1993;1182:291-298.
24. Cheney P. Early management and physiologic changes in crush syndrome. Grit Care Nurs Q 1994;17:62-73.
25. Martinez M. Polyunsaturated fatty acid changes suggesting a new enzymatic defect in Zellweger syndrome. Lipids 1989;24: 261-265.
26. Thomas DW, van Kuijk FJGM, Stephens RJ. Quantitative determination of hydroxy fatty acids as an indicator of m vivo lipid peroxidation: oxidation products of arachidonic and doco-sapentaenoic acids in rat liver after exposure to carbon tetrachloride. Anal Biochem 1992;206:353-358.
27. Wang T, Yu W, Powell WS. Formation of monohydroxy derivatives of arachidonic acid, linoleic acid, and oleic acid during oxidation of low density lipoprotein by copper ions and endothelial cells. J Lipid Res 1992;33:527-537.
28. Nikkari T, Malo-Ranta U, Hiltunen T, Jaakkola O, VläHerttuala S. Monitoring of lipoprotein oxidation by gas chromatographic analysis of hydroxy fatty acids. J Lipid Res 1995; 36:200-207.